AI assistant
Sending…
Niagen Bioscience, Inc. — Director's Dealing 2023
Jun 16, 2023
32418_dirs_2023-06-16_4e60bb13-db5f-4c9c-8abb-a49ccb8ab3db.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2023-06-15
Reporting Person: Ng Wang Yu Gary (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-15 | Stock Option (right to buy) | $1.67 | A | 20000 | Acquired | 2033-06-14 | Common Stock (20000) | Direct |
Footnotes
F1: Option vests 100% on June 15, 2024.
More from Niagen Bioscience, Inc.
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Major Shareholding Notification
2026
Jan 30
Regulatory Filings
2025
Dec 22
Director's Dealing
2025
Nov 17
Regulatory Filings
2025
Nov 6